Balcinrenone
A nonsteroidal antimineralocorticoid drug
| Balcinrenone | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Balcinrenone is a nonsteroidal antimineralocorticoid that was developed for the treatment of congestive heart failure and hypertension. It acts as a selective mineralocorticoid receptor antagonist, blocking the effects of aldosterone in the body.
Mechanism of Action[edit]
Balcinrenone functions by inhibiting the action of aldosterone, a hormone that increases the reabsorption of sodium and water in the kidneys. By blocking aldosterone, balcinrenone promotes the excretion of sodium and water, which helps to lower blood pressure and reduce fluid overload in conditions such as congestive heart failure.
Pharmacokinetics[edit]
Balcinrenone is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The drug has a half-life that allows for once-daily dosing, making it convenient for patients.
Clinical Use[edit]
Balcinrenone was investigated for its potential use in treating conditions like heart failure and hypertension. However, it did not reach the market, and its development was discontinued. Despite this, the study of balcinrenone has contributed to the understanding of mineralocorticoid receptor antagonists and their role in cardiovascular therapy.
Side Effects[edit]
As with other mineralocorticoid receptor antagonists, potential side effects of balcinrenone may include hyperkalemia, hypotension, and renal impairment. Patients taking this class of drugs require monitoring of serum potassium levels and renal function.
Related Compounds[edit]
Balcinrenone is part of a class of drugs known as nonsteroidal antimineralocorticoids. Other drugs in this class include eplerenone and spironolactone, which are used clinically to treat similar conditions.
Research and Development[edit]
The development of balcinrenone was part of a broader effort to create more selective and effective mineralocorticoid receptor antagonists. Although balcinrenone itself was not marketed, research in this area continues to be important for developing new treatments for cardiovascular diseases.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
